Tempest Therapeutics, Inc. — Director's Dealing 2017

Jan 10, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2017-01-05

Reporting Person: Couturier Christophe (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-05	Stock Option (right to buy)	$1.64	A	100000	Acquired	2027-01-05	Common Stock (100000)	Direct

Footnotes

F1: The option vests as to 12.5% of the option shares on January 5, 2017 and vests as to an additional 12.5% of the option shares at the end of each successive three-month period thereafter.